CD68+ TAMs had no prognostic value in predicting the outcome of surgically treated ICC patients, which may be attributed to the inability of CD68 to distinguish between M1 and M2 subsets. This evidence concerns the gene CD68 and intrahepatic cholangiocarcinoma.